Imbalanced economic levels and medical conditions in developing countries also limit the application of precision therapy (Yi et al., 2020) Moreover, due to low PD-L1 expression and poor immunogenicity in prostate cancer, the new anticancer approaches PD-1 and PD-L1 inhibitors have not yet been applied in clinical treatment of prostate cancer (Rathi et al., 2021). This evidence concerns the gene CD274 and prostate carcinoma.